Back to Search
Start Over
Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease.
- Source :
-
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jul 01; Vol. 26 (13), pp. 3481-3490. Date of Electronic Publication: 2020 Jan 09. - Publication Year :
- 2020
-
Abstract
- Purpose: Application of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with hematologic disorders is limited by the development of GVHD. Separation of GVHD and graft-versus-leukemia (GVL) remains a great challenge in the field. We investigated the contribution of individual pathways involved in the complement cascade in GVH and GVL responses to identify specific targets by which to separate these two processes.<br />Experimental Design: We used multiple preclinical murine and human-to-mouse xenograft models involving allo-HCT recipients lacking components of the alternative pathway (AP) or classical pathway (CP)/lectin pathway (LP) to dissect the role of each individual pathway in GVHD pathogenesis and the GVL effect. For translational purposes, we used the AP-specific complement inhibitor, CR2-fH, which localizes in injured target organs to allow specific blockade of complement activation at sites of inflammation.<br />Results: Complement deposition was evident in intestines of mice and patients with GVHD. In a preclinical setting, ablation of the AP, but not the CP/LP, significantly improved GVHD outcomes. Complement activation through the AP in host hematopoietic cells, and specifically dendritic cells (DC), was required for GVHD progression. AP deficiency in recipients decreased donor T-cell migration and Th1/Th2 differentiation, while increasing the generation of regulatory T cells. This was because of decreased activation and stimulatory activity of recipient DCs in GVHD target organs. Treatment with CR2-fH effectively prevented GVHD while preserving GVL activity.<br />Conclusions: This study highlights the AP as a new therapeutic target to prevent GVHD and tumor relapse after allo-HCT. Targeting the AP by CR2-fH represents a promising therapeutic approach for GVHD treatment.<br /> (©2020 American Association for Cancer Research.)
- Subjects :
- Animals
Complement Pathway, Classical drug effects
Complement Pathway, Classical immunology
Dendritic Cells immunology
Dendritic Cells metabolism
Disease Models, Animal
Disease Susceptibility
Hematopoietic Stem Cell Transplantation adverse effects
Hematopoietic Stem Cell Transplantation methods
Humans
Immunophenotyping
Leukemia complications
Leukemia therapy
Mice
Mice, Knockout
Prognosis
T-Lymphocyte Subsets drug effects
T-Lymphocyte Subsets immunology
T-Lymphocyte Subsets metabolism
Transplantation, Homologous
Complement Activation drug effects
Complement System Proteins immunology
Graft vs Host Disease etiology
Graft vs Host Disease prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1557-3265
- Volume :
- 26
- Issue :
- 13
- Database :
- MEDLINE
- Journal :
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publication Type :
- Academic Journal
- Accession number :
- 31919135
- Full Text :
- https://doi.org/10.1158/1078-0432.CCR-19-1717